Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Seeking Alpha
seekingalpha.com > article > 4937036-time-for-intervention-part-2

Time For An Intervention: Part 2

23+ hour, 31+ min ago   (24+ words) Last week we saw a significant spike in the Japanese yen following a joint Japan/US intervention in the currency market. Read more here....

Seeking Alpha
seekingalpha.com > pr > 20478950-igc-pharma-secures-psilocybin-research-authorization-expanding-focus-on-neuropsychiatric

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia (2026-04-20)

3+ mon, 3+ week ago   (152+ words) The authorization, granted under the oversight of the Fondo Nacional de Estupefacientes (FNE), provides IGC Pharma with a regulated capability to work with psilocybin, positioning the Company within an expanding area of scientific and investor interest. The Company believes it…...

Seeking Alpha
seekingalpha.com > pr > 20207851-protagenic-therapeutics-advances-pt00114-into-multiple-dose-phase-1-trial-positioning-for

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders (2025-08-21)

11+ mon, 3+ week ago   (162+ words) Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 Current treatments leave more than half of patients without adequate relief and are burdened by significant side effects. "Initiating the multiple-dose trial of PT00114 marks a pivotal step…...

Seeking Alpha
seekingalpha.com > news > 4519668-neurocrine-biosciences-fails-mid-stage-study-of-depression-drug

Neurocrine Biosciences fails mid-stage study of depression drug

9+ mon, 5+ day ago   (121+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...

Seeking Alpha
seekingalpha.com > news > 4503405-teva-long-acting-antipsychotic-uzedy-gains-indication-bipolar-disorder

Teva long-acting antipsychotic Uzedy gains indication for bipolar disorder

10+ mon, 5+ day ago   (146+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...

Seeking Alpha
seekingalpha.com > news > 4502346-tonix-advance-cyclobenzaprine-into-phase-2-depression

Tonix to advance cyclobenzaprine into phase 2 for depression

10+ mon, 1+ week ago   (118+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...